Playford, E. Geoffrey, Lipman, Jeffrey, Jones, Michael, Lau, Anna F., Kabir, Masrura, Chen, Sharon C.-A., Marriott, Deborah J., Seppelt, Ian, Gottlieb, Thomas, Cheung, Winston, Iredell, Jonathan R., McBryde, Emma S., and Sorrell, Tania C.
Background. Delayed antifungal therapy for invasive candidiasis (IC) contributes to poor outcomes. Predictive risk models may allow targeted antifungal prophylaxis to those at greatest risk. Methods. A prospective cohort study of 6685 consecutive nonneutropenic patients admitted to 7 Australian intensive care units (ICUs) for ⩾72 hours was performed. Clinical risk factors for IC occurring prior to and following ICU admission, colonization with Candida species on surveillance cultures from 3 sites assessed twice weekly, and the occurrence of IC ⩾72 hours following ICU admission or ⩽72 hours following ICU discharge were measured. From these parameters, a risk-predictive model for the development of ICU-acquired IC was then derived. Results. Ninety-six patients (1.43%) developed ICU-acquired IC. A simple summation risk-predictive model using the 10 independently significant variables associated with IC demonstrated overall moderate accuracy (area under the receiver operating characteristic curve = 0.82). No single threshold score could categorize patients into clinically useful high- and low-risk groups. However, using 2 threshold scores, 3 patient cohorts could be identified: those at high risk (score ⩾6, 4.8% of total cohort, positive predictive value [PPV] 11.7%), those at low risk (score ⩽2, 43.1% of total cohort, PPV 0.24%), and those at intermediate risk (score 3-5, 52.1% of total cohort, PPV 1.46%). Conclusions. Dichotomization of ICU patients into high- and low-risk groups for IC risk is problematic. Categorizing patients into high-, intermediate-, and low-risk groupsmay more efficiently target early antifungal strategies and utilization of newer diagnostic tests. [ABSTRACT FROM AUTHOR]